Oculis

News

Black and white close up image of an eye

Oculis takes second eye disease therapy into pivotal trials

Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data.

News

Oculis SA and EBAC join to drive ophthalmology innovation

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisi

News

UK says it has hit target on commercial trial set-up times

The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks